Advice
following an abbreviated submission:
asparaginase (Spectrila®) is accepted for use within NHS Scotland.
Indication under review: as a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years and adults.
Asparaginase produced in E. coli cells has been used in NHS Scotland as an unlicensed medicine as part of treatment of ALL in children and adults; asparaginase (Spectrila®) provides a licensed alternative.
Download detailed advice45KB (PDF)
Medicine details
- Medicine name:
- asparaginase (Spectrila)
- SMC ID:
- 1319/18
- Indication:
- Component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia in paediatric patients from birth to 18 years and adult patients.
- Pharmaceutical company
- Medac Pharmaceuticals
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 09 April 2018